1991
Effect of MK-458 (HPMC) in Parkinson's Disease Previously Untreated With Dopaminergic Drugs. A Double-Blind, Placebo-Controlled Multicenter Study.
Koller WC, Block GA, Ahlskog JE, Ahrens S, Cedarbaum JM, Cyhan G, Goetz CG, LeWitt PA, Liss C, McLean L, Moses H, Muenter M, Nausieda P, Sanchez-Ramos J, Reich S, Singer C, Stellar S, Weiner W. Effect of MK-458 (HPMC) in Parkinson's Disease Previously Untreated With Dopaminergic Drugs. A Double-Blind, Placebo-Controlled Multicenter Study. Clinical Neuropharmacology 1991, 14: 322. PMID: 1913699, DOI: 10.1097/00002826-199108000-00004.Peer-Reviewed Original ResearchMeSH KeywordsAgedDelayed-Action PreparationsDouble-Blind MethodFemaleHumansLactoseMaleMethylcelluloseMiddle AgedOxazinesParkinson DiseaseConceptsMK-458Early Parkinson's diseaseParkinson's diseaseDopaminergic drugsDisability Rating ScoreDopamine receptor agonismPlacebo-controlled evaluationPatient global assessmentClinical rating scalesParkinsonian symptomsAntiparkinsonian efficacyMulticenter studyAdverse reactionsIdeal treatmentReceptor agonistReceptor agonismSustained release formulationPlaceboGlobal assessmentDiseaseRating ScaleSignificant decreaseDrugsPatientsRating scores
1990
Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)
Cedarbaum JM, Silvestri M, Clark M, Toy L, Harts A, Green-Parsons A, McDowell FH. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR). Journal Of Neural Transmission: Parkinson's Disease A And Dementia Section 1990, 2: 205-213. PMID: 2257060, DOI: 10.1007/bf02257651.Peer-Reviewed Original ResearchConceptsStandard SinemetMotor response fluctuationsResponse fluctuationsSinemet CRDisease patientsControlled-release levodopa/carbidopaLevodopa/carbidopaLong-term treatmentParkinson's disease patientsLong-term managementAntiparkinson effectEligible patientsMost patientsMedication dosesInterdose intervalClinical trialsParkinson's diseaseUseful adjunctPatientsSinemetDiseaseYearsCarbidopaAdjunctDosePharmacokinetic and Pharmacodynamic Considerations in Management of Motor Response Fluctuations in Parkinson's Disease
Cedarbaum J. Pharmacokinetic and Pharmacodynamic Considerations in Management of Motor Response Fluctuations in Parkinson's Disease. Neurologic Clinics 1990, 8: 31-49. PMID: 2181267, DOI: 10.1016/s0733-8619(18)30372-4.Peer-Reviewed Original ResearchConceptsMotor response fluctuationsResponse fluctuationsLevodopa-related fluctuationsSynthetic dopamine agonistsPlasma levodopa levelsMajority of patientsPharmacokinetics of levodopaSuch treatment approachesBrain dopaminergic activityLong-term treatmentBrain dopamine levelsRapid systemic clearanceAnti-Parkinson agentsLevodopa levelsDopamine agonistsPharmacodynamic consequencesPharmacodynamic considerationsSystemic clearanceAdvanced PDDopamine levelsDopaminergic activityTherapeutic approachesParkinson's diseaseTreatment approachesGalenic formulationSustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation
Cedarbaum J, Clark M, Toy L, Green‐Parsons A. Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation. Movement Disorders 1990, 5: 298-303. PMID: 1979657, DOI: 10.1002/mds.870050407.Peer-Reviewed Original ResearchConceptsMK-458Disease patientsSelective D2 receptor agonistPostsynaptic dopamine receptorsMotor response fluctuationsD2 receptor agonistParkinson's disease patientsSustained-release formAdjunctive therapyD2 agonistDopamine receptorsSinemetParkinson's diseaseAgonistsResponse fluctuationsProgressive lossPatientsWeeksDiseaseDosageReduced sensitivityDaysTherapyReceptors
1989
The Promise and Limitations of Controlled-Release Oral Levodopa Administration.
Cedarbaum JM. The Promise and Limitations of Controlled-Release Oral Levodopa Administration. Clinical Neuropharmacology 1989, 12: 147. PMID: 2663145, DOI: 10.1097/00002826-198906000-00001.Peer-Reviewed Original ResearchA double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. Journal Of Neurology Neurosurgery & Psychiatry 1989, 52: 207. PMID: 2649640, PMCID: PMC1032507, DOI: 10.1136/jnnp.52.2.207.Peer-Reviewed Original ResearchConceptsStandard Sinemet 25/100Sinemet 25/100Sinemet CR4Controlled-release levodopa/carbidopaDouble-blind crossover comparisonDaily medication dosesDouble-blind partMean interdose intervalLevodopa/carbidopaAntiparkinson effectMedication dosesInterdose intervalSevere dyskinesiaCrossover comparisonCrossover trialParkinsonian patientsTherapeutic responseMedication administrationMotor functionAntiparkinsonian agentsParkinson's diseaseOpen treatmentMotor responsePatientsMotor performance
1988
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Cedarbaum J, Kutt H, McDowell F. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988, 38: 533-6. PMID: 3352906, DOI: 10.1212/wnl.38.4.533.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarbidopaCorpus StriatumDelayed-Action PreparationsDrug CombinationsFemaleHumansLevodopaParkinson DiseaseRatsRats, Inbred StrainsTyrosineConceptsDaily intakeRecent clinical trialsMean daily intakeTotal daily intakeLevodopa intakeStandard SinemetClinical responseLevodopa preparationsBrain uptakeClinical trialsPlasma concentrationsClinical significanceBlood samplingLevodopaTherapeutic efficacyMethyldopa levelsControlled-release formulationPatientsIntakeTime curveAUCSinemetLevelsTrialsControlled-Release Levodopa/Carbidopa III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease.
Cedarbaum JM, Hoey M, Kutt H, McDowell FH. Controlled-Release Levodopa/Carbidopa III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease. Clinical Neuropharmacology 1988, 11: 168. PMID: 3378225, DOI: 10.1097/00002826-198804000-00008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiparkinson AgentsBiological AvailabilityCarbidopaDelayed-Action PreparationsDrug CombinationsDrug EvaluationHumansLevodopaParkinson DiseaseConceptsSinemet CR4Parkinson's diseasePeak plasma levodopa concentrationResponse fluctuationsOpen-label studyAdvanced Parkinson's diseasePlasma levodopa concentrationsStandard SinemetInterdose intervalDaily dosesTherapeutic responseLevodopa concentrationsSame patientLabel studyDiseaseRelative bioavailabilityPatientsGreater delayTreatmentSinemetLevodopaDoses
1987
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Cedarbaum J, Breck L, Kutt H, McDowell F. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology 1987, 37: 1607-12. PMID: 3658164, DOI: 10.1212/wnl.37.10.1607-a.Peer-Reviewed Original ResearchMeSH KeywordsCarbidopaDelayed-Action PreparationsDrug Administration ScheduleDrug CombinationsHumansLevodopaParanoid DisordersParkinson DiseasePatient Acceptance of Health CareTime FactorsConceptsSinemet CR4Interdose intervalParkinson's diseaseResponse fluctuationsTherapeutic response fluctuationsOpen-label trialPlasma levodopa levelsSlow-release preparationAntiparkinsonian effectsStandard levodopaLevodopa dosesLevodopa preparationsLevodopa levelsDaily dosesRelease preparationDiseaseLevodopaDosesProlongationTreatmentOverall benefitSinemetPatientsSlight reductionControlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum J, Breck L, Kutt H, McDowell F. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease. Neurology 1987, 37: 233-41. PMID: 3808304, DOI: 10.1212/wnl.37.2.233.Peer-Reviewed Original ResearchConceptsPlasma levodopa levelsLevodopa levelsResponse fluctuationsParkinson's diseaseControlled-release carbidopa/levodopaCarbidopa/levodopaOpen-label trialBioavailability of levodopaStandard SinemetDisability scoresLevodopa preparationsInterdose intervalDaily dosesParkinson's patientsControlled-release formulationClinical performanceDiseaseLevodopaDay consistencyOverall benefitSinemetPatientsDosesTrialsWeeks